SCHEMBL6474259

SCHEMBL6474259

CCN(CC)c1ccc(CCc2ccc(Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.60
KMT2A Q03164 6/20 0.60
TDP1 Q9NUW8 2/20 0.60
RECQL P46063 1/20 0.60
BLM P54132 1/20 0.60
SIRT2 Q8IXJ6 1/20 0.58
FABP4 P15090 1/20 0.52
NPC1 O15118 4/20 0.52
RAB9A P51151 3/20 0.52
NOX1 Q9Y5S8 3/20 0.52
MAPT P10636 3/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PTGS1 P23219 1/20 0.49
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6474052 0.97 MEN1 (0.58) MEN1KMT2ATDP1RECQLBLM
SCHEMBL6474913 0.95 MEN1 (0.55) MEN1KMT2ATDP1RECQLBLM
SCHEMBL27560781 0.90 MEN1 (0.58) MEN1KMT2ATDP1RECQLBLM
SCHEMBL27560782 0.89 MEN1 (0.61) MEN1KMT2ATDP1RECQLBLM
Hydrochloric Acid SCHEMBL6475141 0.89 MEN1 (0.57) MEN1KMT2ATDP1RECQLBLM
Hydrochloric Acid SCHEMBL6475843 0.88 MEN1 (0.60) MEN1KMT2ATDP1RECQLBLM
SCHEMBL6481765 0.88 MEN1 (0.64) MEN1KMT2ATDP1RECQLBLM
SCHEMBL6475423 0.88 MEN1 (0.56) MEN1KMT2ATDP1RECQLBLM
SCHEMBL6475772 0.86 MEN1 (0.76) MEN1KMT2ATDP1RECQLBLM
SCHEMBL6482938 0.85 MEN1 (0.53) MEN1KMT2ATDP1RECQLBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US claimed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US claimed
CN-1378446-A Method for inhibiting amyloid aggregation and imaging amyloid deposits WARNER LAMBERT CO (US) 2002-11-06 CN claimed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP claimed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO claimed
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
CN-1378446-A Method for inhibiting amyloid aggregation and imaging amyloid deposits WARNER LAMBERT CO (US) 2002-11-06 CN disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885KMT2A 4729/4885TDP1 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.